Vyteris, Inc. (OTC BB: VYTR), the maker of the first active drug delivery patch to receive market approval from the (FDA), was founded with the purpose of developing, manufacturing and commercializing pharmaceutical products based upon novel, advanced drug delivery technology. This technology delivers drugs through the skin using low-level electrical energy, causing little to no disturbance. By utilizing Vyteris’ technology, many of the shortcomings of existing drug delivery methods can be eliminated or minimized. For further information, visit the Company’s web site at www.vyteris.com.
- 18 years ago
QualityStocks
Vyteris, Inc. (OTC BB: VYTR)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Pinterest Inc. (NYSE: PINS) Gains Attention Following Report on $4 Billion AWS AI Investment Initiative
Pinterest (NYSE: PINS) attracted investor attention following a Benzinga report by Shanthi Rexaline highlighting the company's plans to…
-
Bitcoin as a Corporate Treasury Asset: How MindWave Innovations Inc. (NYSE American: APUS) Is Redefining Institutional Yield Infrastructure
MindWave Innovations recently advanced its Bitcoin treasury strategy with up to $100M PIPE and activation…
-
Oncotelic Therapeutics Inc. (OTLC) Combines Nanomedicine, AI, and Robotics to Advance Precision Oncology and Rare Disease Innovation
OTLC continues to advance its Deciparticle nanomedicine platform, with expanding international development initiatives supporting future…